AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01511055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-17
Description: One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
Study NCT03699969 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated dose escalated VMAT
Description: measure the local control, progression free survival and overall survival
Study NCT04982601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Exercises
Description: Yoga-based exercises are Hatha yoga-based sessions consisting of breathing exercises, warm-up exercises, relaxation, asanas exercises.
Study NCT01027273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevent Return of Stroke
Description: Prevent Return of Stroke is a community-based, peer-led stroke recurrence prevention program. This is a bilingual (English/Spanish) education program written at a 4th grade reading level, and contains simple, actionable, messages, easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes, to help reduce stroke recurrence risk factors. It consists of 6 sessions (1½ hours each) held over 6-weeks. Topics include learning the risk factors for stroke, controlling hypertension, LDL cholesterol, preventing blood clots, medication adherence, and stress management.The intervention arm will participate in the intervention shortly after enrolling in the trial.
Study NCT01027273 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prevent Return of Stroke
Description: The intervention arm will participate in the intervention shortly after enrolling in the trial. The usual care arm will be offered the intervention after 12 months from enrolling in the trial.
Study NCT02507960 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The Gamma Pod
Description: Immobilization of breast during radiation.
Study NCT02507960 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CT simulation
Description: See arm description
Study NCT01528865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.~Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.~Subjects will be taking drug for 16 weeks.
Study NCT02335658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5423P
Description: 40-80mg/day
Study NCT04643197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barbed PDS suture (STRATAFIX Symmetric PDS Plus)
Description: STRATAFIX Symmetric PDS Plus is a barbed suture.
Study NCT02758470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 250 mg, taken orally three times per day
Study NCT02758470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methazolamide
Description: 100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.
Study NCT02758470 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be taken three times per day
Study NCT01668043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibody UB-421
Description: UB-421 is administered by intravenous infusion
Study NCT03050567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler Ultrasound
Description: Transcranial Doppler will be performed on the symptomatic (ipsilateral to an index event) middle cerebral artery in a quiet temperature controlled room. The middle cerebral artery will be identified through the temporal window in a supine position with a flow direction towards the probe. The subject will have a head frame (Marc 600 Spencer Technologies, USA) fitted to reduce motion and to secure a constant angle of the middle cerebral artery insonation depth at 50-60 mm from the skull surface. All recordings will be made using the ST3 Transcranial Doppler Ultrasound System (Spencer Technologies, USA) with a 2-MHz transducer for 1 hour. Emboli will be detected by listening for their characteristic short audible sound (range 10-100 ms, intensity threshold above 7 dB) and spectral appearance using the International Consensus Group microembolus identification criteria and an automated Embolus Detection Software (Spencer Technologies, USA).
Study NCT02331732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtually Observed Treatment
Study NCT02331732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Directly Observed Treatment
Study NCT03336970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDTA
Study NCT01762514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine every-other-day regimen
Description: Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy
Study NCT01762514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amifostine everyday regimen
Description: Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
Study NCT01427309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Trivalent Inactivated Influenza Vaccine
Description: 0.5 mL Intramuscular
Study NCT01427309 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Inactivated Influenza Vaccine
Description: 0.5 mL, Intramuscular
Study NCT03047499 — intervention group
Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: Botulinum toxin type-A injection
Study NCT00351364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast Sodium
Description: 100 mg P.O. One time only
Study NCT00351364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast Sodium
Description: 100 mg P.O. One time only
Study NCT03336970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NaOCl
Study NCT03617705 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Skyn Monitor Lab Session 1
Description: Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session.
Study NCT03617705 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Skyn Monitor Field Test with EMA App
Description: After Skyn Monitor Lab Session 1, participants will be instructed to wear Skyn monitor for the rest of the day and the following two weeks. Participants will also enter information on each drinking session during the two week time using a mobile-based ecological momentary assessment (EMA) to collect real-time data in daily life.
Study NCT03617705 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Skyn Monitor Lab Session 2
Description: Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session. Participant will also complete device acceptability and usability survey.
Study NCT04643197 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-barbed PDS suture (PDS Plus)
Description: Non-barbed suture
Study NCT00846274 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SK Antithrombin III
Study NCT00846274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SK Antithrombin III
Study NCT00798447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLF 541
Description: 22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
Study NCT00798447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipofundin MCT
Description: 22-24 h iv.infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
Study NCT05239819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The initial training intensity of the preoperative threshold IMT trainer (DofinTM, Breathing Strength Builder, Taiwan) was moderate to high intensity (≥50% of MIP), which was according to the patient's baseline level and increased by 5-10% per week. The frequency is 25-30 minutes each time, twice a day and five days per week for at least two weeks. The participants would receive at least 10 times training sessions before surgery
Study NCT05239819 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regulated care and education
Description: Regulated care and education will be applied
Study NCT04017156 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: implant installation
Description: All site preparations will be performed deeper compared to the length of the implant so that the implant apex cannot reach the bottom of the osteotomy.
Study NCT00733902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 10 mg at 1 dose every 8 weeks
Study NCT00733902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 5 mg at 1 dose every 8 weeks
Study NCT00733902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 2.5 mg at 1 dose every 8 weeks
Study NCT00733902 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV placebo to match tanezumab at 1 dose every 8 weeks
Study NCT00928070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Fesoterodine 4 mg and 8 mg
Study NCT00928070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sham 4 mg and 8 mg
Study NCT02891421 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Therapeutic Horseback Riding
Description: Veterans were matched to a horse for best fit and the same horse was ridden each week. The warm-up exercises involved various repeated physical movements while the horse was walking or standing steady, such as head rotations, lifting arms, rotating ankles, flexing toes. The exercises began with riding at a walk during the early weeks, learning reining skills and riding positions, and progressed to light trotting. Veteran participants were able to build on skill sets related to grooming, tacking, mounting, and riding that were introduced in prior weeks. Skill progression was based on individual abilities and safety as determined by certified riding instructor and occupational therapist.
Study NCT02891421 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard Care: Participants received standard care
Study NCT01849926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT04017156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant installation
Description: All site preparations will be performed deeper compared to the length of the implant so that the implant apex cannot reach the bottom of the osteotomy.
Study NCT01849926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mecillinam
Study NCT04274439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Pain Education and Exercise
Description: Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a website created and registered especially for the study that will have the shooting of 1 video of pain education and 1 video of exercises for the subjects of the study, totaling 8 videos of pain education and 8 exercise videos. We will provide complimentary materials along with the triggered videos and a booklet of chronic pain information. We will also make weekly calls for a health coaching service and the sending of smartphone messages for the motivation and accountability of the subjects.
Study NCT04274439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Booklet
Description: An online booklet containing information about chronic pain and suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
Study NCT01767402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PhtD vaccine with/without adjuvant
Description: Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.
Study NCT01767402 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax 23TM
Description: One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.
Study NCT01767402 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NaCl
Description: One dose administered intramuscularly in the deltoid region of the right arm at month 2.
Study NCT06423248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Culinary spices
Description: Powdered culinary spices
Study NCT06423248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Culinary spices
Description: Powdered culinary spices
Study NCT03763786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix Acetate
Description: Used a standard
Study NCT03763786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix Acetate
Description: Used a standard
Study NCT01491178 — intervention group
Intervention type: DRUG
Intervention: Prazaxa
Description: Dabigatran etexilate
Study NCT04807894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal Cream with Applicator
Description: Vaginal testosterone 300-μg dose will be compounded with 13.5 mg of testosterone propionate in 0.45 mL of polysorbate National Formulary liquid and sufficient emollient cream base to make 45 g total. A calibrated vaginal applicator will be supplied to measure out doses of 1 g each. All study medications will be compounded by a single pharmacy so as to avoid variation in compounding between pharmacies and allow for control of compounding. Randomization will be conducted by the compounding pharmacy to allow for double-blinding of patients and clinicians.
Study NCT04807894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Cream with Applicator
Description: Vaginal testosterone 300-μg dose will be compounded with 13.5 mg of testosterone propionate in 0.45 mL of polysorbate National Formulary liquid and sufficient emollient cream base to make 45 g total. A calibrated vaginal applicator will be supplied to measure out doses of 1 g each. All study medications will be compounded by a single pharmacy so as to avoid variation in compounding between pharmacies and allow for control of compounding. Randomization will be conducted by the compounding pharmacy to allow for double-blinding of patients and clinicians.
Study NCT04459845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Child Interaction Therapy
Description: Parent-child Interaction therapy (PCIT; Eyberg and Robinson, 1982) s a manualized evidence-based behavioral parent training program that integrates social learning and attachment theories. Parents proceed through two distinct phases: Child-Directed Interaction (CDI) resembles traditional play therapy, and Parent-Directed Interaction (PDI) resembles clinical behavior therapy. During all sessions, the therapist coaches each parent in vivo in their use of the CDI and PDI skills with their child.
Study NCT04459845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child Parent Psychotherapy
Description: Child-parent psychotherapy (CPP; Lieberman et al., 2005) is a relationship-based treatment that integrates attachment, cognitive-behavioral, social-learning, and psychodynamic theories. CPP focuses on the child-parent relationship as a way to improve the child's adaptive functioning. Various treatment strategies are employed including a focus on safety, affect regulation, the joint construction of a trauma narrative, and engagement in developmentally appropriate activities.
Study NCT00827190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILS-920
Study NCT00838357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic = Plerixafor
Description: 240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
Study NCT01528865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg once a day p.o. for 16 weeks.
Study NCT03878693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fomepizole
Description: IV 4-MP.
Study NCT00932516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: South Beach Diet™ with South Beach Diet™ Products
Study NCT00932516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: South Beach Diet™
Study NCT00932516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie restricted diet with South Beach Diet™ Products
Study NCT00932516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie Restricted Diet
Study NCT02744976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months
Study NCT02744976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle recommendations
Description: Standard lifestyle recommendations
Study NCT02744976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle recommendations
Description: Standard lifestyle recommendations
Study NCT01073579 — intervention group
Intervention type: DRUG
Intervention: Sabril®
Description: Infantile Spasms (IS): Initiate therapy at 50 mg/kg/day twice daily increasing total daily dose per instructions to a maximum of 150 mg/kg/day.~Refractory Complex Partial Seizures (rCPS) in Adults: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1.5 grams twice daily.
Study NCT03869814 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: Blood Draw
Study NCT00518518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Staloral 300
Description: Staloral 300
Study NCT03878693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APAP
Description: Oral APAP
Study NCT03878693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APAP
Description: Oral APAP
Study NCT01489111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Bleeding preventive treatment administered i.v. before, during and after surgery. Individually adjusted doses.
Study NCT01889095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Description: patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
Study NCT01889095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH/Reg
Description: patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
Study NCT02828891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two-Dimensional Transcranial Doppler
Description: Transcranial Doppler will be used to measure CSF pressure.
Study NCT02800876 — intervention group
Intervention type: OTHER
Intervention: CT-acquisition
Study NCT00518518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01010542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ILV-095 300 mg in a 4 to 1 ratio
Description: Single dose of ILV-095 300 mg
Study NCT01010542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ILV-095 300 mg in a 4 to 1 ratio
Description: Single dose of Placebo
Study NCT03093402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101
Description: Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
Study NCT03093402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
Study NCT03093402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
Study NCT02033356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block with lidocaine 1%
Description: US-guided adductor canal block
Study NCT02033356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT04690166 — intervention group
Intervention type: OTHER
Intervention: The speech records related to the reading document
Description: The document consists bit, bet, but words and Diyet passage. Volunteers will read the document in front of the microphone and also the speech will recorded by a computer.
Study NCT00738621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant, Dexamethasone, Ondansetron
Description: Aprepitant oral 40mg one dose, dexamethasone IV 4mg one dose, ondansetron 4 mg one dose
Study NCT00738621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aprepitant, Dexamethasone, Placebo
Description: Aprepitant 40mg oral one time, dexamethasone IV 4mg one time placebo one time